Benitec biopharma inc.BNTC.US Overview

US StockHealthcare

(No presentation for BNTC)

Overview AI Analysis AI Earnings Summary Financials Financial Forecast Stock Sentimental Institutions TradingView Chart

BNTC Overall Performance

BNTC AI Analysis & Strategy

BNTC Recent Performance

3.89%

Benitec biopharma inc.

0.81%

Avg of Sector

-1.14%

S&P500

BNTC PowerScanner

BNTC Key Information

BNTC Valuation Metrics

BNTC Earnings Table

BNTC Profile

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.